

PE/Dazzle™ 594 anti-human CD279 (PD-1)

Catalog # / Size: 2249695 / 25 tests
2249700 / 100 tests

Clone: EH12.2H7


Isotype: Mouse IgG1, κ

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with PE/Dazzle™ 594 under optimal conditions. The solution is free of unconjugated PE/Dazzle™ 594 and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Concentration: 0.2



Human peripheral blood lymphocytes were stained with CD3 APC and CD279 (clone EH12.2H7) PE/Dazzle™ 594 (above) or mouse IgG1 PE/Dazzle™ 594 isotype control (below).


Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* PE/Dazzle™ 594 has a maximum excitation of 566 nm and a maximum emission of 610 nm.

Application Notes: Additional reported applications (for the relevant formats) include: blocking of ligand binding¹⁻³ and immunohistochemical staining of paraformaldehyde fixed frozen sections¹³. The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/microg).



- Application** 1. Dorfman DM, *et al.* 2006 *Am. J. Surg. Pathol.* 30:802. (FA)
- References:** 2. Radziewicz H, *et al.* 2007. *J. Virol.* 81:2545. (FA)
3. Velu V, *et al.* 2007. *J. Virol.* 81:5819. (FA)
4. Zahn RC, *et al.* 2008. *J. Virol.* 82:11577. [PubMed](#)
5. Chang WS, *et al.* 2008. *J. Immunol.* 181:6707. (FC) [PubMed](#)
6. Nakamoto N, *et al.* 2009. *PLoS Pathog.* 5:e1000313. (FA)
7. Jones RB, *et al.* 2009. *J. Virol.* 83:8722. (FC) [PubMed](#)
8. Vojnov L, *et al.* 2010. *J. Virol.* 84:753. (FC) [PubMed](#)
9. Radziewicz H, *et al.* 2010. *J. Immunol.* 184:2410. (FC) [PubMed](#)
10. Monteriro P, *et al.* 2011. *J. Immunol.* 186:4618. [PubMed](#)
11. Conrad J, *et al.* 2011. *J. Immunol.* 186:6871. [PubMed](#)
12. Salisch NC, *et al.* 2010. *J. Immunol.* 184:476. (Rhesus reactivity)
13. Li H and Pauza CD. 2015. *Eur. J. Immunol.* 45:298. (IHC)
-

Description: Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.